Related Experiment Video

Updated: Aug 7, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer

D S Ettinger1

  • 1Johns Hopkins Oncology Center, Baltimore, MD, USA.

Seminars in Oncology
|August 2, 2001
PubMed

Insights

New chemotherapy drugs offer improved survival rates for small cell lung cancer patients. Ongoing studies explore combination therapies to further enhance treatment effectiveness against this disease.

Area of Science:

  • Oncology
  • Medical Chemistry

Background:

  • Small cell lung cancer (SCLC) necessitates novel therapeutic strategies to improve patient survival.
  • Current effective agents for SCLC include paclitaxel, docetaxel, topotecan, irinotecan, vinorelbine, gemcitabine, and amrubicin.

Purpose of the Study:

  • To review the efficacy and toxicity of current chemotherapy agents for small cell lung cancer.
  • To highlight the ongoing research into combination chemotherapy for SCLC treatment.

Main Methods:

  • Literature review of existing studies on SCLC chemotherapy agents.
  • Analysis of response rates and median survival data for various drugs.

Main Results:

  • Effective SCLC drugs demonstrate response rates from 27% to 79% in previously untreated patients.
  • Median survival with these agents ranges from 6.6 to 12 months.
  • Leukopenia is identified as the primary toxicity associated with these chemotherapeutic agents.

Conclusions:

  • Current chemotherapy agents provide a range of efficacy in treating small cell lung cancer.
  • Combination chemotherapy strategies are under investigation to potentially improve outcomes and overcome treatment resistance.

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...